Dapsone syndrome in cutaneous lupus erythematosus

Journal of Rheumatology

Volumn 23, Issue 4, 1996, Pages 766-768

  Mok, Chi Chiu ^a   Lau, Chak Sing ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cutaneous lupus erythematosus; Dapsone; Idiosyncratic reaction; Sulfone

Indexed keywords

AMPICILLIN; ANTIHISTAMINIC AGENT; DAPSONE; HYDROXYCHLOROQUINE; PREDNISONE;

ADULT; ARTICLE; CASE REPORT; DAPSONE SYNDROME; FATALITY; FEMALE; HUMAN; HYPOALBUMINEMIA; LUPUS ERYTHEMATOSUS; MALE; PRIORITY JOURNAL; RASH; SKIN DISEASE;

ADULT; DAPSONE; FATAL OUTCOME; FEMALE; HUMANS; LEPROSTATIC AGENTS; LUPUS ERYTHEMATOSUS, CUTANEOUS; MALE; SYNDROME;

EID: 0029892123     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. World Health Organization: Advances in malaria chemotherapy. Report of a WHO Scientific Group. Technical Report Series 711. WHO, Geneva, 1984.
2. Coleman MD: Dapsone: Modes of action, toxicity and possible strategies for increasing patient tolerance. Br J Dermatol 1993;129:507-13.
3. Editorial. Adverse reactions to dapsone. Lancet 1981,2:184-5.
4. Lowe J: Treatment of leprosy with diaminodiphenylsulphone by mouth. Lancet 1950;1:145-50.
5. Allday EJ, Barnes J: Toxic effects of diaminodiphenyl sulphone in the treatment of leprosy. Lancet 1951;2:205-6.
6. Johnson DA, Cattau EL Jr, Kuritsky JN, Zimmerman HJ: Liver involvement in the sulphone syndrome. Arch Intern Med 1986;146:875-7.
7. Krans A, Jakez J, Palacios A: Dapsone induced sulphone syndrome and systemic lupus exacerbation (letter). J Rheumatol 1992;19:178-80.
8. Coleman MD, Jacobus DP: Reduction of dapsone hydroxylamine to dapsone during methaemoglobin formation in human erythrocytes in vitro. II. Movement of dapsone across a semipermeable membrane into erythrocytes and plasma. Biochem Pharmacol 1993;46.1363-8